A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application (Q38163290)

30 August 2017

title

A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application (English)

1 reference

30 August 2017

Tasuku Honjo

1 reference

30 August 2017

Sidonia Fagarasan

1 reference

30 August 2017

Taku Okazaki

1 reference

30 August 2017

Shunsuke Chikuma

series ordinal

1 reference

30 August 2017

Yoshiko Iwai

series ordinal

1 reference

30 August 2017

language of work or name

English

0 references

publication date

1 December 2013

1 reference

30 August 2017

1 reference

30 August 2017

1 reference

30 August 2017

1 reference

30 August 2017

page(s)

1212-1218

1 reference

Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor

30 August 2017

cites work

1 reference

Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice

21 January 2018

1 reference

Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes

21 January 2018

1 reference

PD-1 deficiency reveals various tissue-specific autoimmunity by H-2b and dose-dependent requirement of H-2g7 for diabetes in NOD mice

21 January 2018

1 reference

Hydronephrosis associated with antiurothelial and antinuclear autoantibodies in BALB/c-Fcgr2b-/-Pdcd1-/- mice

21 January 2018

1 reference

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

21 January 2018

1 reference

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

21 January 2018

1 reference

SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation

21 January 2018

1 reference

PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine

21 January 2018

1 reference

CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms

21 January 2018

1 reference

Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2.

21 January 2018

1 reference

PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta

21 January 2018

1 reference

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

21 January 2018

1 reference

PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells

21 January 2018

1 reference

PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells

21 January 2018

1 reference

Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family

21 January 2018

1 reference

Treg and CTLA-4: two intertwining pathways to immune tolerance

21 January 2018

1 reference

Structural and functional analysis of the costimulatory receptor programmed death-1.

21 January 2018

1 reference

Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2

21 January 2018

1 reference

The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors

21 January 2018

1 reference

Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes

21 January 2018

1 reference

Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4-CD8-) thymocytes

21 January 2018

1 reference

Expression of programmed death 1 ligands by murine T cells and APC

21 January 2018

1 reference

Tissue expression of PD-L1 mediates peripheral T cell tolerance.

21 January 2018

1 reference

Severe functional impairment and elevated PD-1 expression in CD1d-restricted NKT cells retained during chronic HIV-1 infection

21 January 2018

1 reference

PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice

21 January 2018

1 reference

Regulation of PD‐1, PD‐L1, and PD‐L2 expression during normal and autoimmune responses

21 January 2018

1 reference

PD-1 and its ligands in tolerance and immunity

21 January 2018

1 reference

Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice

21 January 2018

1 reference

Non-specific immunoadsorption in patients with dilated cardiomyopathy: mechanisms and clinical effects

21 January 2018

1 reference

A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans

21 January 2018

1 reference

Association of a putative regulatory polymorphism in the PD-1 gene with susceptibility to type 1 diabetes

21 January 2018

1 reference

Programmed cell death 1 inhibits inflammatory helper T-cell development through controlling the innate immune response

21 January 2018

1 reference

Characterization of the major histocompatibility complex class II binding site on LAG-3 protein

21 January 2018

1 reference

Cutting edge: molecular analysis of the negative regulatory function of lymphocyte activation gene-3

21 January 2018

1 reference

Foxp3 programs the development and function of CD4+CD25+ regulatory T cells

21 January 2018

1 reference

Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death

21 January 2018

1 reference

Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease

21 January 2018

1 reference

Rescue of the autoimmune scurfy mouse by partial bone marrow transplantation or by injection with T-enriched splenocytes

21 January 2018

1 reference

TGF-beta: a master of all T cell trades

21 January 2018

1 reference

TGF-beta and CD4+CD25+ regulatory T cells

21 January 2018

1 reference

Plasticity of Foxp3(+) T cells reflects promiscuous Foxp3 expression in conventional T cells but not reprogramming of regulatory T cells.

21 January 2018

1 reference

Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses

21 January 2018

1 reference

Structural basis for co-stimulation by the human CTLA-4/B7-2 complex

21 January 2018

1 reference

Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4

21 January 2018

1 reference

Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses

21 January 2018

1 reference

T-Independent immune response: new aspects of B cell biology

21 January 2018

1 reference

Programmed cell death 1 suppresses B-1b cell expansion and long-lived IgG production in response to T cell-independent type 2 antigens

21 January 2018

1 reference

21 January 2018

1 reference

Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme

21 January 2018

1 reference

Role of CXCR5 and CCR7 in follicular Th cell positioning and appearance of a programmed cell death gene-1high germinal center-associated subpopulation.

21 January 2018

1 reference

Foxp3+ follicular regulatory T cells control the germinal center response.

21 January 2018

1 reference

Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions

21 January 2018

1 reference

Regulation of the germinal center reaction by Foxp3+ follicular regulatory T cells

21 January 2018

1 reference

IL-21 acts directly on B cells to regulate Bcl-6 expression and germinal center responses

21 January 2018

1 reference

IL-21 regulates germinal center B cell differentiation and proliferation through a B cell-intrinsic mechanism

21 January 2018

1 reference

Essential role of IL-21 in B cell activation, expansion, and plasma cell generation during CD4+ T cell-B cell collaboration

21 January 2018

1 reference

PD-1-mediated suppression of IL-2 production induces CD8+ T cell anergy in vivo

21 January 2018

1 reference

STAT5 protein negatively regulates T follicular helper (Tfh) cell generation and function.

21 January 2018

1 reference

STAT5 is a potent negative regulator of TFH cell differentiation

21 January 2018

1 reference

The receptor PD-1 controls follicular regulatory T cells in the lymph nodes and blood.

21 January 2018

1 reference

PD-1 inhibits antiviral immunity at the effector phase in the liver

21 January 2018

1 reference

Restoring function in exhausted CD8 T cells during chronic viral infection

21 January 2018

1 reference

T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion

21 January 2018

1 reference

PD-1+ memory phenotype CD4+ T cells expressing C/EBPalpha underlie T cell immunodepression in senescence and leukemia

21 January 2018

1 reference

Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells.

21 January 2018

1 reference

IFN-α directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity

21 January 2018

1 reference

NFATc1 regulates PD-1 expression upon T cell activation.

21 January 2018

1 reference

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

21 January 2018

1 reference

Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity

21 January 2018

1 reference

PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells

21 January 2018

1 reference

Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target

21 January 2018

1 reference

PD-1 and PD-1 ligands: from discovery to clinical application

21 January 2018

1 reference

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

21 January 2018

1 reference

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

Tumor Immunotherapy Directed at PD-1

21 January 2018

1 reference

Enhancement of vaccine-induced primary and memory CD8(+) T-cell responses by soluble PD-1.

21 January 2018

1 reference

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

21 January 2018

1 reference

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

21 January 2018

1 reference

PDCD1: a tissue-specific susceptibility locus for inherited inflammatory disorders

21 January 2018

1 reference

PD-1 deficiency results in the development of fatal myocarditis in MRL mice

21 January 2018

1 reference

Tyrosine phosphorylation controls internalization of CTLA-4 by regulating its interaction with clathrin-associated adaptor complex AP-2

21 January 2018

2 references

21 January 2018

12 December 2020

The inhibitory receptor PD-1 regulates IgA selection and bacterial composition in the gut

1 reference

12 December 2020

Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death

2 references

12 December 2020

7 January 2021

inferred from DOI database lookup

B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma

1 reference

12 December 2020

Cutting edge: lymphoproliferative disease in the absence of CTLA-4 is not T cell autonomous

1 reference

12 December 2020

Tolerance and cancer: a critical issue in tumor immunology.

1 reference

12 December 2020

Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity

1 reference

12 December 2020

Identifiers

DOI

10.1038/NI.2762

1 reference

30 August 2017

1 reference